AE Wealth Management LLC Acquires 1,253 Shares of Edwards Lifesciences Corporation $EW

AE Wealth Management LLC lifted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 1.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 91,755 shares of the medical research company’s stock after purchasing an additional 1,253 shares during the period. AE Wealth Management LLC’s holdings in Edwards Lifesciences were worth $7,176,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Nuveen LLC purchased a new position in Edwards Lifesciences during the first quarter valued at $330,881,000. Jennison Associates LLC increased its stake in shares of Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after acquiring an additional 2,576,383 shares in the last quarter. Mirova US LLC lifted its position in Edwards Lifesciences by 56.2% during the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after acquiring an additional 1,054,301 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Edwards Lifesciences during the 2nd quarter valued at about $67,832,000. Finally, Woodline Partners LP boosted its stake in Edwards Lifesciences by 7,805.0% during the first quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock worth $59,822,000 after acquiring an additional 814,917 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on EW. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. Truist Financial upped their price target on Edwards Lifesciences from $87.00 to $90.00 and gave the stock a “hold” rating in a research note on Monday, November 3rd. Oppenheimer lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $91.39.

Insider Buying and Selling

In other news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider directly owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Up 1.1%

EW opened at $83.37 on Monday. The firm’s 50 day simple moving average is $77.78 and its two-hundred day simple moving average is $77.41. Edwards Lifesciences Corporation has a 1-year low of $64.89 and a 1-year high of $87.09. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $48.38 billion, a PE ratio of 12.00, a PEG ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the firm posted $0.67 EPS. The firm’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.